Barbara Santevecchi, PharmD, BCIDP

Clinical Assistant Professor

Department: Pharmacy Education and Practice

Business Phone: (352) 594-5892

Business Email: bsantevecchi@ufl.edu

CV: View Curriculum Vitae

About Barbara Santevecchi

Barbara Santevecchi joined the College of Pharmacy as a Clinical Assistant Professor in the Department of Pharmacy Education and Practice in August 2019. She serves as an Infectious Diseases Clinical Pharmacy Specialist and member of the Antimicrobial Management Program at UF Health Shands Hospital. She received her Doctor of Pharmacy degree from Wingate University School of Pharmacy in Wingate, North Carolina in 2015. Following graduation, she completed PGY1 Pharmacy Practice and PGY2 Infectious Diseases pharmacy residencies at the Medical University of South Carolina in Charleston, South Carolina. After completing residency training, she worked as an Infectious Diseases Clinical Pharmacist at Atrium Health in Charlotte, North Carolina. Barbara is a board certified infectious diseases pharmacist. Her research interests include HIV/AIDS, microbiology, rapid diagnostics, novel agents for multidrug resistant infections, and antimicrobial stewardship. Barbara has published research in several peer-reviewed journals and has delivered presentations on her research at national meetings. She is an active member of the Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, and American Association of Colleges of Pharmacy.

Accomplishments

Board Certification (BCIDP) Committee Vice Chair

2023-2024 · Society of Infectious Diseases Pharmacists

Exemplary Clinician Award

2022-2023 · University of Florida College of Pharmacy

Teaching Service Award

2021 · University of Florida College of Pharmacy

Media Excellence Award

2020 · University of Florida College of Pharmacy

Preceptor of the Year

2019-2020 · UF Health Shands Hospital Pharmacy Residency Program

Member

2016-Current · Infectious Diseases Society of America

Member

2013-Current · American College of Clinical Pharmacy

Teaching Profile

Courses Taught

2019-2024

PHA5788C Patient Care 6

2020-2025

PHA5782C Patient Care 2: Introduction to Infectious Disease and Oncology

2020

PHA5755 Micro, Immun, Virol

2019

PHA5163L Prac Skills Lab III

2021-2025

PHA5784C Pt Care 4: GI and Renal

2021-2025

PHA5876C Pt Care 8 Complex Pts

Board Certifications

Board Certified Infectious Diseases Pharmacist

Board of Pharmacy Specialties

Research Profile

Research Interests: Microbiology, rapid diagnostics, HIV/AIDS, novel agents for multidrug resistant infections, antimicrobial stewardship

Publications

Academic Articles

2024

Ampicillin-Sulbactam for Carbapenem-Susceptible Acinetobacter baumannii Pneumonia: A Case for High-Dose, Continuous Infusion Dosing Strategy in the Trauma ICU.

Surgical infections. 25(7):553-557 [DOI] 10.1089/sur.2024.135. [PMID] 38958001.

PubMed · Publisher’s Site

2024

Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV.

International journal of STD & AIDS. 35(8):651-653 [DOI] 10.1177/09564624241238813. [PMID] 38502040.

1 citation · PubMed · Publisher’s Site

2023

Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI).

JAC-antimicrobial resistance. 5(2) [DOI] 10.1093/jacamr/dlad021. [PMID] 36936190.

2 citations · PubMed · Publisher’s Site

2022

Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.

Antimicrobial agents and chemotherapy. 66(2) [DOI] 10.1128/AAC.02046-21. [PMID] 34902271.

9 citations · PubMed · Publisher’s Site

2022

Impact of Empiric Linezolid for Necrotizing Soft Tissue Infections on Duration of Methicillin-Resistant Staphylococcus aureus-Active Therapy.

Surgical infections. 23(3):313-317 [DOI] 10.1089/sur.2021.329. [PMID] 35133888.

4 citations · PubMed · Publisher’s Site

2022

Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 79(18):1586-1591 [DOI] 10.1093/ajhp/zxac171. [PMID] 35704702.

11 citations · PubMed · Publisher’s Site

2022

Pharmacy student self-assessment of strength of residency candidacy compared to clinical faculty.

Currents in pharmacy teaching & learning. 14(3):304-309 [DOI] 10.1016/j.cptl.2022.01.017. [PMID] 35307089.

PubMed · Publisher’s Site

2022

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)

Antimicrobial Stewardship & Healthcare Epidemiology. 2(1) [DOI] 10.1017/ash.2022.21. [PMID] 36310806.

6 citations · PubMed · Publisher’s Site

2021

Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course.

Currents in pharmacy teaching & learning. 13(2):152-158 [DOI] 10.1016/j.cptl.2020.09.010. [PMID] 33454072.

1 citation · PubMed · Publisher’s Site

2021

Implementation of a comprehensive intervention focused on hospitalized patients with HIV by an existing stewardship program: successes and lessons learned.

Therapeutic advances in infectious disease. 8 [DOI] 10.1177/20499361211010590. [PMID] 33953916.

2 citations · PubMed · Publisher’s Site

2020

Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.

The Annals of pharmacotherapy. 54(12):1252-1259 [DOI] 10.1177/1060028020933772. [PMID] 32517480.

6 citations · PubMed · Publisher’s Site

2018

Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.

International journal of antimicrobial agents. 51(4):629-635 [DOI] 10.1016/j.ijantimicag.2018.01.016. [PMID] 29408227.

23 citations · PubMed · Publisher’s Site

2018

In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.

Open forum infectious diseases. 5(7) [DOI] 10.1093/ofid/ofy158. [PMID] 30046642.

18 citations · PubMed · Publisher’s Site

2015

Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.

The Annals of pharmacotherapy. 49(5):566-81 [DOI] 10.1177/1060028015570729. [PMID] 25680759.

36 citations · PubMed · Publisher’s Site

Grants

Jun 2024 ACTIVE

Real-World, Multicenter Experience with Ceftazidime/Avibactam in the Pediatric Population

Role: Principal Investigator

Funding: MEDICAL UNIV OF SOUTH CAROLINA via ABBVIE

Jun 2021 ACTIVE

A retrospective chart review study of cefiderocol real world outcomes and safety in the treatment of patients with Gram-negative bacterial infections (GNBI) in the US and Europe

Role: Principal Investigator

Funding: SHIONOGI INC

May 2021 – Jul 2024

Prevalence of Cefazolin Inoculum Effect in Mcthicillin Susceptible Staphylococcus aureus Bacteremia

Role: Co-Project Director/Principal Investigator

Funding: UF HEALTH SHANDS HOSPITAL

Education

Pharm.D.

2015 · Wingate University School of Pharmacy

Contact Details

Phones:

Business:: (352) 594-5892

Emails:

Business:: bsantevecchi@ufl.edu

Addresses:

Business Mailing:: PO Box 100486
GAINESVILLE FL 32610
Business Street:: PO Box 100486
GAINESVILLE FL 32610